Cellectar Announces Positive Data for Iopofosine I 131 in r/r WM
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 14 2026
0mins
Source: Newsfilter
- Successful Financing: Cellectar completed a financing of up to $140 million to support the confirmatory study of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) and FDA accelerated approval, ensuring adequate funding for key regulatory milestones.
- Impressive Clinical Data: The CLOVER-WaM Phase 2b study reported a 61.8% major response rate and a median duration of response of 17.8 months among 55 patients, demonstrating consistent efficacy in both BTK inhibitor-exposed and refractory patients, bolstering confidence for FDA accelerated approval.
- New Study Initiation: Cellectar has dosed the first patient in the Phase 1b trial of CLR 125 for triple-negative breast cancer, with early dosimetry, safety, and efficacy data expected by mid-2026, further expanding its radiopharmaceutical pipeline to address significant unmet medical needs.
- Improved Financial Position: As of March 31, 2026, Cellectar reported cash and cash equivalents of $8.3 million, down from $13.2 million in December 2025, but the new financing is expected to support operations into Q2 2027, ensuring continued investment in R&D.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CLRB?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CLRB
About CLRB
Cellectar Biosciences, Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on the discovery, development, and commercialization of drugs for treatment of cancer. The Company, through its phospholipid ether drug conjugate (PDC) delivery platform, is focused on developing PDCs that are designed to specifically target cancer cells. Its PDC platform possesses the potential for the discovery and development of cancer-targeting treatments, and it plans to develop PDCs both independently and through research and development collaborations. Its lead programs are: Iopofosine I 131 (iopofosine), a beta-emitting iodine-131-based program which has been studied extensively; CLR 121225, an actinium-225-based program; and CLR 121125, an iodine-125 Auger-emitting program. Iopofosine evaluation is ongoing in a Phase IIb study in r/r multiple myeloma and central nervous system lymphoma patients and the CLOVER-2 Phase Ib study for pediatric patients with high grade gliomas.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cellectar Biosciences Q1 2026 Earnings Call Highlights
- Positive Clinical Data: Cellectar Biosciences reported positive 12-month follow-up data from the Phase IIb CLOVER WaM study in Q1 2026, demonstrating an overall response rate of 83.6% and a major response rate of 61.8%, indicating significant efficacy and tolerability of its drug iopofosine, potentially paving the way for accelerated FDA approval.
- Successful Financing: The company completed an oversubscribed financing of up to $140 million, including $35 million upfront and up to $105 million in milestone-based capital, which will materially strengthen its financial position and support operations into the second quarter of 2027.
- R&D Expenses: In Q1 2026, Cellectar incurred approximately $3 million in research and development expenses and $2.8 million in general and administrative expenses, resulting in a net loss of $5.7 million; however, the company ended the quarter with $8.3 million in cash and cash equivalents, reflecting efforts to manage costs effectively.
- Future Outlook: The company plans to initiate a randomized controlled Phase III confirmatory study in late Q4 2026, primarily evaluating progression-free survival, with expectations to submit a new drug application in the second half of 2027, which could present new growth opportunities if approved.
See More
Cellectar Biosciences Reports Q1 2026 Financial Results
- Financial Performance: Cellectar Biosciences reported a Q1 2026 non-GAAP EPS of -$1.33, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $8.3 million, a significant decrease from $13.2 million as of December 31, 2025, highlighting increased liquidity pressure.
- Financing Activities: Despite the cash decline, the company secured approximately $31 million in net proceeds from a May 2026 offering, which is expected to improve future funding conditions and support R&D initiatives.
- Market Reaction: Given the poor financial data, market reactions to Cellectar Biosciences may lead to stock price volatility, prompting investors to closely monitor the company's financial health and strategic adjustments.
See More
Cellectar Announces Positive Data for Iopofosine I 131 in r/r WM
- Successful Financing: Cellectar completed a financing of up to $140 million to support the confirmatory study of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) and FDA accelerated approval, ensuring adequate funding for key regulatory milestones.
- Impressive Clinical Data: The CLOVER-WaM Phase 2b study reported a 61.8% major response rate and a median duration of response of 17.8 months among 55 patients, demonstrating consistent efficacy in both BTK inhibitor-exposed and refractory patients, bolstering confidence for FDA accelerated approval.
- New Study Initiation: Cellectar has dosed the first patient in the Phase 1b trial of CLR 125 for triple-negative breast cancer, with early dosimetry, safety, and efficacy data expected by mid-2026, further expanding its radiopharmaceutical pipeline to address significant unmet medical needs.
- Improved Financial Position: As of March 31, 2026, Cellectar reported cash and cash equivalents of $8.3 million, down from $13.2 million in December 2025, but the new financing is expected to support operations into Q2 2027, ensuring continued investment in R&D.
See More
Cellectar Biosciences to Announce Q1 Earnings on May 14
- Earnings Announcement Date: Cellectar Biosciences is set to release its Q1 earnings report on May 14 before the market opens, drawing significant attention given the company's ongoing financial challenges.
- EPS Expectations: The consensus EPS estimate stands at -$1.89, reflecting a staggering 1250% year-over-year decline, which indicates severe difficulties in profitability that could negatively impact investor confidence.
- Revenue Forecast: The consensus revenue estimate is $0, highlighting the company's significant challenges in generating income, which may affect its future financing capabilities and operational strategies.
- Estimate Revision Trends: Over the past three months, there has been one upward revision and no downward revisions to EPS estimates, suggesting a cautiously optimistic outlook from analysts regarding the company's future performance, although the overall outlook remains bleak.
See More
Cellectar Biosciences Achieves Phase 2 Trial Success
- Significant Clinical Results: Cellectar Biosciences' Phase 2b CLOVER WaM trial demonstrated an overall response rate of 83.6% and a major response rate of 61.8% for patients with relapsed or refractory Waldenström macroglobulinemia, successfully meeting its primary endpoint and indicating the therapy's potential in blood cancer treatment.
- Financing Plan to Boost Development: The company announced a financing deal that could raise up to $140 million, including $35 million in upfront payments and $105 million tied to future milestones, providing crucial funding to support the development of Iopofosine I 131 and enhancing its market competitiveness.
- Surge in Investor Confidence: Cellectar's stock surged over 27% on Tuesday, reaching a six-month high, as investor optimism grew following strong clinical trial results and the financing plan, reflecting the market's confidence in the company's future prospects.
- Optimistic Market Expectations: Retail investor sentiment for Cellectar shifted to 'extremely bullish', with expectations that the stock could approach $7, nearly doubling in value, indicating strong confidence in the company's growth potential moving forward.
See More
Cellectar Biosciences Secures $140M in Capital Raising
- Innovative Financing Structure: Cellectar Biosciences has entered agreements with institutional investors and management to raise approximately $35 million in upfront funding, with potential access to up to $105 million in milestone-based securities, indicating strong market appeal.
- Securities Issuance Method: The financing is structured as a registered direct offering of common stock alongside a concurrent private placement, involving common stock, pre-funded warrants, and milestone-based warrants, enhancing investor participation flexibility.
- Clear Use of Proceeds: The funds raised are expected to support the development of the company's targeted oncology therapies pipeline, underscoring Cellectar's strategic focus on cancer treatment and future growth potential.
- Positive Market Reaction: Cellectar Biosciences' shares surged 51.6% in premarket trading, reflecting investor optimism regarding the company's financing plan and its anticipated impact on future performance.
See More
Cellectar Biosciences Q1 2026 Earnings Call Highlights
- Positive Clinical Data: Cellectar Biosciences reported positive 12-month follow-up data from the Phase IIb CLOVER WaM study in Q1 2026, demonstrating an overall response rate of 83.6% and a major response rate of 61.8%, indicating significant efficacy and tolerability of its drug iopofosine, potentially paving the way for accelerated FDA approval.
- Successful Financing: The company completed an oversubscribed financing of up to $140 million, including $35 million upfront and up to $105 million in milestone-based capital, which will materially strengthen its financial position and support operations into the second quarter of 2027.
- R&D Expenses: In Q1 2026, Cellectar incurred approximately $3 million in research and development expenses and $2.8 million in general and administrative expenses, resulting in a net loss of $5.7 million; however, the company ended the quarter with $8.3 million in cash and cash equivalents, reflecting efforts to manage costs effectively.
- Future Outlook: The company plans to initiate a randomized controlled Phase III confirmatory study in late Q4 2026, primarily evaluating progression-free survival, with expectations to submit a new drug application in the second half of 2027, which could present new growth opportunities if approved.
See More
Cellectar Biosciences Reports Q1 2026 Financial Results
- Financial Performance: Cellectar Biosciences reported a Q1 2026 non-GAAP EPS of -$1.33, indicating challenges in profitability that could undermine investor confidence.
- Cash Position: As of March 31, 2026, the company had cash and cash equivalents of $8.3 million, a significant decrease from $13.2 million as of December 31, 2025, highlighting increased liquidity pressure.
- Financing Activities: Despite the cash decline, the company secured approximately $31 million in net proceeds from a May 2026 offering, which is expected to improve future funding conditions and support R&D initiatives.
- Market Reaction: Given the poor financial data, market reactions to Cellectar Biosciences may lead to stock price volatility, prompting investors to closely monitor the company's financial health and strategic adjustments.
See More
Cellectar Announces Positive Data for Iopofosine I 131 in r/r WM
- Successful Financing: Cellectar completed a financing of up to $140 million to support the confirmatory study of Iopofosine I 131 in relapsed/refractory Waldenström Macroglobulinemia (r/r WM) and FDA accelerated approval, ensuring adequate funding for key regulatory milestones.
- Impressive Clinical Data: The CLOVER-WaM Phase 2b study reported a 61.8% major response rate and a median duration of response of 17.8 months among 55 patients, demonstrating consistent efficacy in both BTK inhibitor-exposed and refractory patients, bolstering confidence for FDA accelerated approval.
- New Study Initiation: Cellectar has dosed the first patient in the Phase 1b trial of CLR 125 for triple-negative breast cancer, with early dosimetry, safety, and efficacy data expected by mid-2026, further expanding its radiopharmaceutical pipeline to address significant unmet medical needs.
- Improved Financial Position: As of March 31, 2026, Cellectar reported cash and cash equivalents of $8.3 million, down from $13.2 million in December 2025, but the new financing is expected to support operations into Q2 2027, ensuring continued investment in R&D.
See More
Cellectar Biosciences to Announce Q1 Earnings on May 14
- Earnings Announcement Date: Cellectar Biosciences is set to release its Q1 earnings report on May 14 before the market opens, drawing significant attention given the company's ongoing financial challenges.
- EPS Expectations: The consensus EPS estimate stands at -$1.89, reflecting a staggering 1250% year-over-year decline, which indicates severe difficulties in profitability that could negatively impact investor confidence.
- Revenue Forecast: The consensus revenue estimate is $0, highlighting the company's significant challenges in generating income, which may affect its future financing capabilities and operational strategies.
- Estimate Revision Trends: Over the past three months, there has been one upward revision and no downward revisions to EPS estimates, suggesting a cautiously optimistic outlook from analysts regarding the company's future performance, although the overall outlook remains bleak.
See More
Cellectar Biosciences Achieves Phase 2 Trial Success
- Significant Clinical Results: Cellectar Biosciences' Phase 2b CLOVER WaM trial demonstrated an overall response rate of 83.6% and a major response rate of 61.8% for patients with relapsed or refractory Waldenström macroglobulinemia, successfully meeting its primary endpoint and indicating the therapy's potential in blood cancer treatment.
- Financing Plan to Boost Development: The company announced a financing deal that could raise up to $140 million, including $35 million in upfront payments and $105 million tied to future milestones, providing crucial funding to support the development of Iopofosine I 131 and enhancing its market competitiveness.
- Surge in Investor Confidence: Cellectar's stock surged over 27% on Tuesday, reaching a six-month high, as investor optimism grew following strong clinical trial results and the financing plan, reflecting the market's confidence in the company's future prospects.
- Optimistic Market Expectations: Retail investor sentiment for Cellectar shifted to 'extremely bullish', with expectations that the stock could approach $7, nearly doubling in value, indicating strong confidence in the company's growth potential moving forward.
See More
Cellectar Biosciences Secures $140M in Capital Raising
- Innovative Financing Structure: Cellectar Biosciences has entered agreements with institutional investors and management to raise approximately $35 million in upfront funding, with potential access to up to $105 million in milestone-based securities, indicating strong market appeal.
- Securities Issuance Method: The financing is structured as a registered direct offering of common stock alongside a concurrent private placement, involving common stock, pre-funded warrants, and milestone-based warrants, enhancing investor participation flexibility.
- Clear Use of Proceeds: The funds raised are expected to support the development of the company's targeted oncology therapies pipeline, underscoring Cellectar's strategic focus on cancer treatment and future growth potential.
- Positive Market Reaction: Cellectar Biosciences' shares surged 51.6% in premarket trading, reflecting investor optimism regarding the company's financing plan and its anticipated impact on future performance.
See More
